Guanidine Derivative ADS1017, a Potent Histamine H3 Receptor Antagonist with Promising Analgesic Activity and Satisfactory Safety Profile

ACS Chem Neurosci. 2024 Dec 18;15(24):4441-4457. doi: 10.1021/acschemneuro.4c00480. Epub 2024 Dec 9.

Abstract

In this study, we selected 12 guanidine derivatives from the previously described ligand library and determined their affinity at histamine H3 and H4 receptors (H3R and H4R, respectively). Moreover, we also checked their intrinsic activity toward H3R and muscarinic M1, M2, and M4 receptors (M1R, M2R, and M4R, respectively). Since ADS1017 has been proved to be the most selective and highly potent H3 antagonist in our series, we chose it as the lead structure for further biological evaluation. To extend the study of its in vivo efficacy, we proposed an alternative synthetic route that resulted in an increased yield. Interestingly, ADS1017 showed a broad spectrum of analgesic activity in both nociceptive and neuropathic pain models. Finally, as a result of comprehensive analysis of its off-target activity and ADMETox parameters, we confirmed the moderate selectivity of ADS1017 and its promising drug-like properties.

Keywords: ADMETox properties; functional characterization; guanidines; histamine H3 receptor; multi-target directed ligand; muscarinic receptors; pain.

MeSH terms

  • Analgesics* / pharmacology
  • Animals
  • Disease Models, Animal
  • Guanidine / analogs & derivatives
  • Guanidine / chemistry
  • Guanidine / pharmacology
  • Guanidines / pharmacology
  • Histamine H3 Antagonists* / chemistry
  • Histamine H3 Antagonists* / pharmacology
  • Humans
  • Male
  • Mice
  • Neuralgia / drug therapy
  • Receptors, Histamine H3* / drug effects
  • Receptors, Histamine H3* / metabolism

Substances

  • Analgesics
  • Histamine H3 Antagonists
  • Receptors, Histamine H3
  • Guanidines
  • Guanidine